ReviewJournal of clinical and translational hepatology2020
HEV and HBV Dual Infection: A Review.
Review in Journal of clinical and translational hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study.Nature communications · 2025Trial
- Analysis of the epidemiological trends of hepatitis A and E in Zhejiang Province and clinical characteristics of severe patients.BMC infectious diseases · 2026Article
- The silent spread of Hepatitis E in India - from epidemiological insight to public health action: a comprehensive review.Infection · 2026Review
- Low HBV replication does not aggravate disease progression in patients with superinfection with HEV.Scientific reports · 2025Article
- Low prevalence of concurrent active hepatitis E and B virus infection in high-risk groups in Southwestern Cameroon.IJID regions · 2025Article
- Prevalence of Hepatitis E genotype 3 among liver disease patients in Southwestern Nigeria.Virology journal · 2025Article
- Serological and molecular characterization of hepatitis E virus and co-infections during the 2014 Biratnagar outbreak in Nepal.BMC infectious diseases · 2025Article
- Bioinformatics Analysis of the Key lncRNAs of the Viral Response Pathway in HepG2 Expressing Genotype IV Swine Hepatitis E Virus ORF3.Microorganisms · 2025Article
- Global Trends and Cross-country Inequalities of Acute Hepatitis E in the Elderly, 1990-2021: A Comprehensive Analysis.Journal of clinical and translational hepatology · 2025Article
- Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations.Vaccines · 2025Review
- A novelJHEP reports : innovation in hepatology · 2025Article
- Epidemiological and clinical impact of hepatitis E virus coinfection in chronic hepatitis B infected patients in Hebei, China.Frontiers in microbiology · 2025Article
- Current knowledge on the epidemiology and detection methods of hepatitis E virus in China.Virology journal · 2024Review
- Increasing trends in hepatitis E hospitalisations in Spain, 1997 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- From discovery to treatment: tracing the path of hepatitis E virus.Virology journal · 2024Review
- Hepatitis E Virus: What More Do We Need to Know?Medicina (Kaunas, Lithuania) · 2024Review
- Evaluation and Immunogenicity of Combined Liposome-Based Vaccine Candidates against Hepatitis E and B Viruses in Rhesus Monkeys.Vaccines · 2024Article
- Clinical characteristics and risk factors of Hepatitis E virus infection in Zhejiang Province: a multicenter case-control study.Frontiers in public health · 2024Article
- Hepatitis E infection: A review.World journal of virology · 2023Review
- A multispecies competitive nanobody-based ELISA for the detection of antibodies against hepatitis E virus.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is a global health problem, affecting about 20 million people worldwide. There is significant overlap of hepatitis B virus (HBV) and HEV endemicity in many Asian countries where dual infections with HEV and HBV can occur. Though the clinical course of HEV is largely self-limited, HEV superinfection in patients with chronic hepatitis B (CHB) can result in acute exacerbation of underlying CHB. HEV superinfection in patients with CHB-related cirrhosis has been identified as a risk factor for decompensated cirrhosis and an independent predictor of mortality. Whereas acute HEV infection in pregnancy can cause fulminant liver failure, the few studies on pregnant patients with dual HBV and HEV infection have shown a subclinical course. Immunosuppression is a risk factor for the development of chronic HEV infection, which can be managed by decreasing the dose of immune-suppressants and administering ribavirin. Vaccination for HEV has been developed and is in use in China but its efficacy in patients with CHB has yet to be established in the USA. In this review, we appraise studies on dual infection with HEV and HBV, including the effect of HEV superinfection and coinfection in CHB, management strategies used and the role of active vaccination in the prevention of HEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.